With money and momentum flowing out of the biotech sector, there are
going to be a lot of beaten-down diamonds in the rough amidst the
wreckage. I'm not entirely convinced PTC Therapeutics (PTCT)
is a diamond, or at least not yet. While the company's lead compound
ataluren has a lot of promise, there some serious questions and concerns
about the drug. Bulls are right about the high-end potential here, but
prior trial failures shouldn't be ignored.
Read more here:
PTC Therapeutics Looks Like A High-Risk Play On Rare Diseases
No comments:
Post a Comment